What Is Exenatide Used For? Approved Uses, Per the Label

Exenatide is a prescription medicine in the glucagon like peptide 1 (GLP-1) receptor agonist class, supplied as an injection and marketed in the United States under brand names including Byetta (exenatide injection, twice daily) and Bydureon BCise (exenatide extended release, once weekly). Its approved use, as stated in United States prescribing information, is confined to glycemic control in type 2 diabetes mellitus. This page summarises that labelled use, the published trials most often associated with it, and the regulatory path of the products. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment. Broader background on the molecule is collected in the exenatide overview.

The approved use in one sentence

United States labelling for exenatide products describes the medicine as indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The twice daily injection is labelled for adults. The extended release product sold as Bydureon BCise carries an indication that includes adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. No other condition appears in the indications and usage section of these labels.

Label revision dates change as safety sections are updated, so the current prescribing information for each specific product is the only authoritative source for the exact present wording, and it is published in the FDA label repositories and in DailyMed. Whether any particular person fits a labelled indication is a question for a prescribing clinician, not for a reference page.

Limitations of use stated on the labels

Alongside the indication, exenatide labelling carries limitations of use. These state that the products are intended for type 2 diabetes mellitus and are not indicated for type 1 diabetes mellitus or for diabetic ketoacidosis. Labelling for the extended release product also includes a boxed warning regarding thyroid C cell tumours observed in rodents, with contraindications covering a personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. Those sections sit outside the indication itself but define the population the label describes.

What the class does, as described in reviews

A 2021 state of the art review of GLP-1 receptor agonists in type 2 diabetes described the shared pharmacology of the class, including enhancement of glucose dependent insulin secretion, suppression of glucagon release, slowing of gastric emptying and effects on food intake (PMID 33068776). An earlier 2003 development review described exenatide as a synthetic version of exendin-4 being advanced by Amylin and Eli Lilly for type 2 diabetes, summarising the preclinical and early clinical rationale that preceded approval (PMID 12808888). Other agents share the mechanism without sharing the molecule, and a 2013 review of lixisenatide described that separate exendin based agent and its own development for type 2 diabetes (PMID 24086950).

Trials associated with the labelled indication

The once weekly development program

The extended release formulation was supported by a multi trial development program. A 2011 analysis of that program reported efficacy and safety outcomes for exenatide once weekly 2 mg across a range of background therapies, including diet and exercise alone and oral glucose lowering drugs, and described glycemic control and tolerability findings pooled across those settings (PMID 21732798). The study set summarised there is the body of work usually cited when the once weekly product is discussed in the context of its glycemic indication.

Cardiovascular outcomes

EXSCEL assessed cardiovascular safety rather than creating a new indication. In that randomised trial, 14,752 patients with type 2 diabetes received once weekly exenatide 2 mg or placebo, and researchers reported that the primary composite outcome of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 11.4 percent of the exenatide group and 12.2 percent of the placebo group, a hazard ratio of 0.91 with a 95 percent confidence interval of 0.83 to 1.00 (PMID 28910237). The trial reported that this met the prespecified criterion for noninferiority on safety, while the difference was not significant for superiority on efficacy (PMID 28910237).

Head to head comparison within the class

SUSTAIN 3 compared two once weekly agents in type 2 diabetes. Over 56 weeks, the study reported a mean HbA1c reduction of 1.5 percentage points with semaglutide 1.0 mg compared with 0.9 percentage points with exenatide extended release 2.0 mg, and a mean body weight reduction of 5.6 kg compared with 1.9 kg (PMID 29246950). Comparative trials of this kind inform clinical choice within the class; they do not alter the wording of either product label.

Regulatory history of the indication

The indications for exenatide products have been expanded by formulation and by age group rather than by disease area. The table below summarises the publicly documented regulatory sequence in the United States.

Availability of individual presentations has changed over time as manufacturers discontinued or consolidated products, which affects what can be dispensed but not what the surviving labels say about the indication. The current status of any single product is recorded in FDA listings.

Conditions studied in trials that are not approved indications

Several randomised studies have tested exenatide outside diabetes, and none of these conditions appears as an approved indication on United States exenatide labelling. A 2017 review examined whether exenatide should be considered a treatment for Parkinson's disease and described the trial evidence available at that time as preliminary (PMID 28777758); a randomised trial tested prehospital exenatide in hyperglycemic stroke (PMID 31518433); a randomised placebo controlled trial investigated exenatide once weekly in alcohol use disorder (PMID 36066977); a proof of concept trial reported that long acting exenatide did not prevent cognitive decline in mild cognitive impairment (PMID 38565814); and a 2006 review of obesity pharmacotherapies discussed incretin based approaches among emerging options, while weight management is not an exenatide label indication (PMID 16924165). Research activity of this kind sits outside the indications and usage section and should be read as investigation rather than as approved use.

Adverse Events: What Studies Report

Safety findings reported in the published trials shape the warnings and adverse reactions sections of the labels, which are separate from the indication.

• In the pooled analysis of the once weekly development program, researchers reported that gastrointestinal effects and injection site reactions were among the tolerability findings described across background therapy groups (PMID 21732798).
• In SUSTAIN 3, the study reported gastrointestinal events as the most frequent adverse events in both treatment groups, with injection site reactions occurring more often with exenatide extended release (PMID 29246950).
• In EXSCEL, researchers reported that rates of the primary safety composite did not differ significantly between once weekly exenatide 2 mg and placebo over a median follow up of more than three years (PMID 28910237).
• A 2014 case report described acute kidney injury in a patient receiving exenatide, an individual observation rather than a controlled trial result (PMID 25672206).
• The 2021 class review described hypoglycemia risk as largely tied to combination with insulin secretagogues or insulin, alongside gastrointestinal tolerability as the dominant class effect (PMID 33068776).

Full warnings, contraindications and adverse reaction frequencies for each product are listed in that product's current prescribing information.

How to read label language without over reading it

An indication describes the population and purpose for which a regulator has judged benefit to outweigh risk based on submitted evidence. It is narrower than the list of conditions a drug has been studied in, and narrower than the mechanisms a review might describe. For exenatide, the indicated purpose is improvement of glycemic control in type 2 diabetes mellitus as an adjunct to diet and exercise. Changes in body weight observed in trials such as SUSTAIN 3 were reported as outcomes in diabetes populations (PMID 29246950), and cardiovascular results in EXSCEL were reported as safety findings in a diabetes population (PMID 28910237), rather than as separate approved uses.

Questions that belong with a prescribing clinician

Decisions about whether a labelled indication applies to an individual, how exenatide compares with other options for a given person, and how any product interacts with existing medicines or kidney function are clinical judgements. A licensed prescriber with access to a person's history and laboratory results is the appropriate source for those answers. This page describes published findings and regulatory status only and contains no dosing information.

References

• GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art (Molecular Metabolism, 2021)
• Exenatide. Amylin/Eli Lilly (Current Opinion in Investigational Drugs, 2003)
• Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies (Diabetes Technology & Therapeutics, 2011)
• Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (New England Journal of Medicine, 2017)
• Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3) (Diabetes Care, 2018)
• Lixisenatide for the treatment of type 2 diabetes (Drugs of Today, 2013)
• Is Exenatide a Treatment for Parkinson's Disease? (Journal of Parkinson's Disease, 2017)
• Prehospital exenatide in hyperglycemic stroke-A randomized trial (Acta Neurologica Scandinavica, 2019)
• Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial (JCI Insight, 2022)
• Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial (Journal of Endocrinological Investigation, 2024)
• Obesity: new perspectives and pharmacotherapies (Cardiology in Review, 2006)
• Exenatide induced acute kidney injury (Journal of Ayub Medical College Abbottabad, 2014)